Publications: Miss Elena Pontarini
Colafrancesco S, Priori R, Smith CG, Minniti A, Iannizzotto V, Pipi E, Lucchesi D, Pontarini E et al.(2020).
CXCL13 as biomarker for histological involvement in Sjögren's syndrome. Rheumatology (United Kingdom)
vol. 59,
(1)
165-170.
Pucino V, Certo M, Bulusu V, Cucchi D, Goldmann K, Pontarini E, Haas R, Smith J et al.(2019).
Lactate Buildup at the Site of Chronic Inflammation Promotes Disease by Inducing CD4+ T Cell Metabolic Rewiring. Cell Metabolism
Prediletto E, Pontarini E, Lucchesi D, Corsiero E, Pratesi F, Migliorini P, Pitzalis C, Bombardieri M (2019).
Synovial fluid fibroblast-like synoviocytes enhance long-term survival of EBV infected memory B cells in rheumatoid arthritis. EUROPEAN JOURNAL OF IMMUNOLOGY.
vol. 49,
791-791.
Grigoriadou S, Chowdhury F, Pontarini E, Tappuni A, Bowman SJ, Bombardieri M(2019).
B-cell depletion with rituximab in the treatment of primary Sjögren's syndrome: What have we learnt?. Clinical and Experimental Rheumatology
vol. 37,
S217-S224.
Nocturne G, Pontarini E, Bombardieri M, Mariette X(2019).
Lymphomas complicating primary Sjögren's syndrome: from autoimmunity to lymphoma. Rheumatology (Oxford)
Pontarini E, Lucchesi D, Fossati-Jimack L, Coleby R, Tentorio P, Croia C, Bombardieri M, Mavilio D(2019).
NK cell recruitment in salivary glands provides early viral control but is dispensable for tertiary lymphoid structure formation. Journal of Leukocyte Biology
vol. 105,
(3)
589-602.
Notarstefano C, Croia C, Pontarini E, Lucchesi D, Sutcliffe N, Tappuni A, Donati V, Pitzalis C et al.(2018).
A clinical and histopathological analysis of the anti-centromere antibody positive subset of primary Sjögren's syndrome. Clin Exp Rheumatol
vol. 36 Suppl 112,
(3)
145-149.
Pontarini E, Lucchesi D, Bombardieri M(2018).
Current Views on the Pathogenesis of Sjögren's Syndrome. Current Opinion in Rheumatology
(2)
215-221.
Pontarini E, Lucchesi D, Bombardieri M(2018).
Current views on the pathogenesis of Sjögren's syndrome. Current Opinion in Rheumatology
vol. 30,
(2)
215-221.
Hudspeth K, Donadon M, Cimino M, Pontarini E, Tentorio P, Preti M, Hong M, Bertoletti A et al.(2016).
Human liver-resident CD56<sup>bright</sup>/CD16<sup>neg</sup> NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways. Journal of Autoimmunity
vol. 66,
40-50.
Pontarini E, Fabris M, Quartuccio L, Cappeletti M, Calcaterra F, Roberto A, Curcio F, Mavilio D et al.(2015).
Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome. Rheumatology (United Kingdom)
vol. 54,
(8)
1429-1434.
Fabris M, Dolcetti R, Pasini E, Quartuccio L, Pontarini E, Salvin S, Ponzoni M, Scott CA et al.(2014).
High prevalence of chlamydophila psittaci subclinical infection in italian patients with sjögren's syndrome and parotid gland marginal zone B-cell lymphoma of MALT-type. Clinical and Experimental Rheumatology
vol. 32,
(1)
61-65.
Mikulak J, Bozzo L, Roberto A, Pontarini E, Tentorio P, Hudspeth K, Lugli E, Mavilio D(2014).
Dopamine inhibits the effector functions of activated NK cells via the upregulation of the D5 receptor. Journal of Immunology
vol. 193,
(6)
2792-2800.
Rusmini M, Griseri P, Matera I, Pontarini E, Ravazzolo R, Mavilio D, Ceccherini I(2014).
Expression variability and function of the RET gene in adult peripheral blood mononuclear cells. Journal of Cellular Physiology
vol. 229,
(12)
2027-2037.
Quartuccio L, Fabris M, Pontarini E, Salvin S, Zabotti A, Benucci M, Manfredi M, Biasi D et al.(2014).
The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: Results of an italian multicentre study. Annals of the Rheumatic Diseases
vol. 73,
(4)
716-721.
Hudspeth K, Pontarini E, Tentorio P, Cimino M, Donadon M, Torzilli G, Lugli E, Della Bella S et al.(2013).
The role of natural killer cells in autoimmune liver disease: A comprehensive review. Journal of Autoimmunity
vol. 46,
55-65.
Quartuccio L, Salvin S, Fabris M, Maset M, Pontarini E, Isola M, De Vita S(2013).
Blys upregulation in Sjö gren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (United Kingdom)
vol. 52,
(2)
276-281.
Fabris M, Quartuccio L, Vital E, Pontarini E, Salvin S, Fabro C, Zabotti A, Benucci M et al.(2013).
The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers. Arthritis and Rheumatism
vol. 65,
(1)
88-97.
Stinco G, Fabris M, Pasini E, Pontarini E, Patriarca MM, Piccirillo F, De Vita S, Dolcetti R(2012).
Detection of DNA of Chlamydophila psittaci in subjects with psoriasis: A casual or a causal link?. British Journal of Dermatology
vol. 167,
(4)
926-928.
Quartuccio L, Maset M, De maglio G, Pontarini E, Fabris M, Mansutti E, Mariuzzi L, Pizzolitto S et al.(2012).
Role of oral cyclophosphamide in the treatment of giant cell arteritis. Rheumatology (United Kingdom)
vol. 51,
(9)
1677-1686.
Fabris M, Quartuccio L, Lombardi S, Saracco M, Atzeni F, Carletto A, Cimmino M, Fabro C et al.(2012).
The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. Autoimmunity Reviews
vol. 11,
(5)
315-320.
Fabris M, De Vita S, Pasini E, Quartuccio L, Pontarini E, Lombardi S, Fabro C, Sarzi-Puttini P et al.(2011).
Chlamydophila psittaci subclinical infection in chronic polyarthritis. Clinical and Experimental Rheumatology
vol. 29,
(6)
977-982.
Ceccarelli F, Perricone C, Fabris M, Alessandri C, Iagnocco A, Fabro C, Pontarini E, De Vita S et al.(2011).
Transforming growth factor β 869C/T and interleukin 6 -174G/C polymorphisms relate to the severity and progression of bone-erosive damage detected by ultrasound in rheumatoid arthritis. Arthritis Research and Therapy
vol. 13,
(4)
Fabris M, Quartuccio L, Lombardi S, Benucci M, Manfredi M, Saracco M, Atzeni F, Morassi P et al.(2010).
Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximabin rheumatoid arthritis. Reumatismo
vol. 62,
(4)
253-258.
Fabris M, de Vita S, Blasone N, Visentini D, Pezzarini E, Pontarini E, Fabro C, Quartuccio L et al.(2010).
Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF iga in the follow-up of patients with rheumatoid arthritis treated with rituximab. Autoimmunity Highlights
vol. 1,
(2)
87-94.